title: Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential.
abstract: In February 2013, ado-trastuzumab emtansine (T-DM1, Kadcyla®) received regulatory approval in the United States for treatment-refractory human epidermal growth factor receptor 2 (HER2) positive metastatic or locally advanced breast cancer based on results from EMILIA, a large phase III trial that compared standard of care lapatinib plus capecitabine to T-DM1. Several other studies have been reported in the metastatic setting and multiple trials are ongoing or planned in the neoadjuvant, adjuvant and advanced disease settings. Here we provide an updated and comprehensive review of clinical trials evaluating T-DM1, discuss management of toxicity associated with this drug, propose potential mechanisms of resistance and offer practical considerations for the treating oncologist.
authors.affiliation: Division of Hematology Oncology, University of California, Los Angeles, USA.
authors.forename: Parvin F
authors.initials: PF
authors.lastname: Peddi
authors.affiliation: Division of Hematology Oncology, University of California, 10945 Le Conte Avenue, PVUB Suite 3360, Los Angeles, CA 90095, USA.
authors.forename: Sara A
authors.initials: SA
authors.lastname: Hurvitz
keywords: HER2; T-DM1; ado-trastuzumab emtansine; antibody-drug conjugate; breast cancer